PROPHYLAXIS OF L. TROPICA INFECTIONS WITH CYCLOSPORINES
用环孢菌素预防热带乳杆菌感染
基本信息
- 批准号:3436589
- 负责人:
- 金额:$ 6.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1985
- 资助国家:美国
- 起止时间:1985-09-30 至 1988-01-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The proposed study on the prophylaxis of Leishmania tropica infections in
Balb/c mice with the known immunosuppressant Cyclosporine A and its
analogue, B-5-49, will attempt to elucidate the drug-induced alteration in
the host response to the parasite which enables this highly susceptible
mouse strain to mount an effective curative immune response to the
infecting protozoa. Leishmania tropica infections in Balb/c mice have been
used as experimental models of both diffuse cutaneous and the frequently
fatal systemic leishmaniasis in man. Our understanding, treatment and
prevention of these two world-wide infections is strikingly incomplete or
inadequate. It is hoped that this study will help to clarify the important
immunomodulatory effects of the two cyclosporines which apparently prevents
leishmania specific immunosuppression from developing during the infectious
process. After determining the optimum protective treatment regimen for
both drugs, the antigen-specific and non-specific immune responsiveness of
infected, treated animals will be monitored and compared to non-treated
controls. Specifically, the development and level of: 1) delayed type
hypersensitivity, 2) anti-leishmanial antibodies and 3) resistance to
parasite challenge will be determined over time as well as level of immune
responsiveness in vitro in response to unrelated antigens (SRBC) and
mitogens. Of particular interest will be the ability of lymphocytes from
the experimental animals to produce lymphokines which are capable of
stimulating macrophage cidal activity toward intracellular leishmania. The
level of immunosuppression in treated, non-infected animals will also be
determined to clearly establish the level of immunocompetence following the
chosen treatment regimen for both drugs.
拟开展的预防热带利什曼原虫感染的研究
用已知的免疫抑制剂环孢菌素A及其
类似物,B-5-49,将试图阐明药物诱导的改变,
宿主对寄生虫的反应使这种高度易感的
小鼠品系,以建立有效的治疗性免疫反应,
感染原生动物 Balb/c小鼠中的热带利什曼原虫感染已经被证实是
用作弥漫性皮肤和经常
致命的系统性利什曼病的人。我们的理解,治疗和
对这两种全球性感染的预防是惊人的不完全,
不足 希望这项研究将有助于澄清重要的
两种环孢菌素的免疫调节作用,
利什曼原虫特异性免疫抑制在感染过程中的发展
过程 在确定了最佳的保护性治疗方案后,
这两种药物,抗原特异性和非特异性免疫反应,
将监测感染的治疗动物,并与未治疗动物进行比较
对照 具体而言,发展和水平:1)延迟型
超敏反应,2)抗利什曼抗体和3)对
寄生虫挑战将随着时间的推移以及免疫水平的确定,
体外对无关抗原(SRBC)的反应性,
有丝分裂原 特别令人感兴趣的将是淋巴细胞的能力,
实验动物产生淋巴因子,
刺激巨噬细胞对细胞内利什曼原虫的杀灭活性。 的
治疗的未感染动物中的免疫抑制水平也将
确定明确建立免疫活性水平后,
选择两种药物的治疗方案。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Prophylactic treatment of BALB/c mice with cyclosporine A and its analog B-5-49 enhances resistance to Leishmania major.
用环孢素 A 及其类似物 B-5-49 对 BALB/c 小鼠进行预防性治疗可增强对重大利什曼原虫的抵抗力。
- DOI:
- 发表时间:1986
- 期刊:
- 影响因子:0
- 作者:Behforouz,NC;Wenger,CD;Mathison,BA
- 通讯作者:Mathison,BA
Immunomodulation of murine leishmaniasis with cyclosporin A.
用环孢菌素 A 对小鼠利什曼病进行免疫调节。
- DOI:10.1007/978-1-4757-5421-6_36
- 发表时间:1988
- 期刊:
- 影响因子:0
- 作者:Behforouz,NC;Wenger,CD
- 通讯作者:Wenger,CD
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NANCY C BEHFOROUZ其他文献
NANCY C BEHFOROUZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NANCY C BEHFOROUZ', 18)}}的其他基金
MACROPHAGE ACTIVATION IN EXPERIMENTAL LEISHMANIASIS
实验性利什曼病中的巨噬细胞激活
- 批准号:
3436686 - 财政年份:1988
- 资助金额:
$ 6.43万 - 项目类别:














{{item.name}}会员




